ClinicalTrials.gg
CompletedNCT05211869T1D-CATCHUpdated Nov 12, 2026Results posted

T1D-CATCH Protocol: Collaboration Around Technology Using Community Health Workers for Young Adults With Type 1 Diabetes

An interventional study of T1D-CATCH in Diabetes, Type 1 Diabetes and Young Adult, sponsored by Albert Einstein College of Medicine. Completed at 1 site in United States. Open to participants aged 18 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Primary conditionDiabetes Mellitus, Type 1Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 1
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 1, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Albert Einstein College of Medicine · Not applicable, Interventional, and Health services research

How we know

Updated Nov 12, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
119
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 11 studies in Diabetes Mellitus, Type 1 by Albert Einstein College of Medicine — 1 open to participants now, 2 under way, none of them phase 3. Diabetes Mellitus, Type 1 · Albert Einstein College of Medicine.

Enrollment
Largest of 11
119 · median 18
Started
2022
with 1 other
No phase
4 of 11
1 open now
Registered
10th of 11
by date

Among the 11 studies in Diabetes Mellitus, Type 1 by Albert Einstein College of Medicine, this one has the largest enrollment, is one of 2 that started in 2022, is one of 4 with no phase, and was the 10th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

1 of the 11 studies in Diabetes Mellitus, Type 1 by Albert Einstein College of Medicine is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 18 Years to 35 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Diabetes Mellitus, Type 1 by Albert Einstein College of Medicine, or all of them as a file.
02

Study summary

The objective of this study is to test the early effects and implementation of an enhanced community health worker (CHW) model (T1D-CATCH) that encourages and supports diabetes technology use in young adults from underrepresented minority groups (YA-URMs) with type 1 diabetes (T1D). The investigators will conduct a 9-month randomized controlled trial in which YA-URMs will be randomized to T1D-CATCH or usual care. The investigators will recruit from adult and pediatric endocrinology and primary care practices in a large safety-net health system in the Bronx, New York. Our specific aims are to 1) evaluate T1D-CATCH effects on technology initiation and continued use over 6 months and 2) evaluate T1D-CATCH implementation using Proctor's Taxonomy of Implementation Outcomes: feasibility, adoption, fidelity, and cost.

Read the detailed description

The study will involve a 9-month randomized control trial of usual care versus T1D-CATCH, an intervention that enhances core community health worker (CHW) service roles to support increased use of T1D technology in young adults (underrepresented minorities) (YA-URM's). Participants will be recruited from primary and specialty care practices at Montefiore Medical Center in the Bronx, New York, which is a large safety-net hospital system in one of the poorest counties in the U.S. Two young adult-aged CHWs from the Montefiore CHW program will be trained extensively per our Supporting Emerging Adults with Diabetes (SEAD) program manuals. For YA-URMs, CHWs will conduct hands-on diabetes technology education, goal-setting, peer support, and social service linkage. CHWs will also help shift insurance approval tasks away from busy providers and better align patient-provider priorities through close communication between the YA-URM and provider. Group sessions will be optional and will follow the YA-centric education curriculum developed in Dr. Agarwal's Supporting Emerging Adults with Diabetes (SEAD) program.

03

Conditions studied

  • Diabetes
  • Type 1 Diabetes
  • Young Adult
  • Diabetes Mellitus

Browse trials for

04

In context

Diabetes Mellitus, Type 1 Reclassified

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

This study's enrollment of 119 is above the median of 40 across 2,824 interventional studies indexed under Diabetes Mellitus, Type 1.

Browse Diabetes Mellitus, Type 1 studies →

Lead sponsor

Albert Einstein College of Medicine is the lead sponsor of 201 studies on the registry; 21 are open to participants now.

Of its 46 completed or terminated interventional studies of FDA-regulated products, 37 (80%) have results posted.

Compared within Diabetes Mellitus, Type 1, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • T1D duration ≥6 months
  • 18-35 years old
  • Self-identified URM status: non-Hispanic Black or Hispanic
  • English- or Spanish-speaking
  • Not currently on a connected diabetes technology system (includes never offered, prescribed but not started within 3 months of receiving the device, discontinued, or previously refused technology)

Exclusion criteria

Exclusion Criteria:

  • Developmental or sensory disability interfering with study participation
  • Current pregnancy
  • Participation in another behavioral or diabetes technology intervention study in the past 6 months.
06

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
119 participants (actual)

Study arms

  • Experimental
    T1D-CATCH

    The CHW intervention will consist of both individual and optional group sessions with YA-URMs with T1D. In individual sessions, CHWs will provide T1D technology education, peer support, and social needs management. Over the 9-month study period, session frequency will involve weekly individual sessions based on participant technology milestones and an optional monthly CHW-led peer group support session. CHW individual and group sessions will be held via videoconferencing or in person, per participant preference and institutional COVID-19 rules.

    Behavioral: T1D-CATCH

  • No intervention
    Usual Care Control Condition

    Control arm participants will receive usual primary or endocrine care at Montefiore. Usual care consists of a physician or nurse practitioner visit with review of blood sugars and treatment decisions based on provider experience. Physicians in endocrinology practices are nested within a diabetes center with access to diabetes nurse practitioners/educators, dieticians, a psychologist, and nurses. In all practices, patients are recommended to see their physician or nurse practitioner every 3 months and attend individual or group sessions.

Interventions

  • BehavioralT1D-CATCH

    As defined by the Centers for Disease Control and Prevention (CDC), a CHW is "a frontline public health worker who is a trusted member of a community or who has a thorough understanding of the community being served, and leverages this unique position to link health systems, social services, and communities". CHWs engender trust with patients by having direct community and lived experience, offering specific support and empathy that may be difficult for other diabetes care professionals to provide. In addition, CHWs have firsthand understanding of cultural barriers to traditional western healthcare and can promote patient-centered culturally-relevant care. They enhance team-based care by helping providers with extra outreach, social needs management, time-consuming tasks, and aligning patient-provider priorities. CHWs in this project will provide social needs assessment and management, introduction to diabetes technologies, and support for onboarding to technology.

07

What researchers measure

Primary outcomes

  1. Technology Initiation

    Technology initiation will be assessed by the percentage of participants initiating diabetes technology and will be reported as a binary variable (yes/no). Technology will include any combination of continuous glucose monitor (CGM), insulin pump, or CGM and insulin pump. Technology initiation will be defined as at least 1 week of first use during the 6-month period following intervention. Data will be ascertained from electronic medical record (EMR) prescriptions, participant self-reporting, CHW dashboard, and device platform data. Variables will be summarized by study group using summary statistics with counts/percentages.

    Time frame: Up to 6 months after initiating intervention

Secondary outcomes

  1. Technology Initiation

    Technology initiation will be assessed by the percentage of participants initiating diabetes technology and will be reported as a binary variable (yes/no). Technology will include any combination of continuous glucose monitor (CGM), insulin pump, or CGM and insulin pump. Technology initiation will be defined as at least 1 week of first use during the 3-month period following intervention. Data will be ascertained from electronic medical record (EMR) prescriptions, participant self-reporting, CHW dashboard, and device platform data. Variables will be summarized by study group using summary statistics with counts/percentages.

    Time frame: Up to 3 months after initiating intervention

  2. Continued Technology Use - Percent Use

    Continued technology use by study end will be determined from device platform metrics detailing days/percent time used, in addition to self-report. Per standard diabetes technology clinical trial guidelines, CGM use is defined as pump use \>90% time. The percentage of time used (% used) will be summarized by study arm using basic descriptive statistics. A target of at least 90% CGM wear-time is associated with the best outcomes for glycemic control.

    Time frame: 9 months following intervention

  3. Continued Technology Use - Days of Wear

    Continued technology use by study end will be determined from device platform metrics detailing days/percent time used, in addition to self-report. Per standard diabetes technology clinical trial guidelines, CGM use is defined as ≥ 5/7 days wear over the 9 month period. Days of wear will be summarized study arm using basic descriptive statistics. A target of at least 5/7 days of CGM wear-time is associated with the best outcomes for glycemic control.

    Time frame: 9 months following intervention

Other outcomes

  1. Feasibility Check

    Post-intervention interviews examining intervention content, complexity, comfort, delivery, and credibility

    Time frame: 6 months (post-intervention)

  2. Adoption

    Measured by recruitment logs

    Time frame: 9 months (post-intervention)

  3. Adoption

    Measured by electronic medical records (EMR)

    Time frame: 9 months (post-intervention)

  4. Adoption

    Measured by young adult participant consent rates

    Time frame: 9 months (post-intervention)

  5. Adoption

    Measured by percentage of provider opt-in

    Time frame: 9 months (post-intervention)

  6. Adoption

    Measured by CHW communications

    Time frame: 9 months (post-intervention)

  7. Fidelity

    Measured by the community health worker (CHW) dashboard

    Time frame: Baseline

  8. Fidelity

    Measured by electronic medical records (EMR) to analyze session attendance

    Time frame: Baseline

  9. Fidelity

    Measured by content delivery

    Time frame: Baseline

  10. Fidelity

    Measured by community health workers (CHW) dashboard

    Time frame: 3 month mark

  11. Fidelity

    Measured by CHW session recordings

    Time frame: 3 month mark

  12. Fidelity

    Measured by EMR to analyze session attendance

    Time frame: 3 month mark

  13. Fidelity

    Measured by content delivery

    Time frame: 3 month mark

  14. Fidelity

    Measured by insurance tasks

    Time frame: 3 month mark

  15. Fidelity

    Measured by CHW dashboard

    Time frame: 6 month mark

  16. Fidelity

    Measured by CHW session recordings

    Time frame: 6 month mark

  17. Fidelity

    Measured by EMR to analyze session attendance

    Time frame: 6 month mark

  18. Fidelity

    Measured by content delivery

    Time frame: 6 month mark

  19. Fidelity

    Measured by insurance tasks

    Time frame: 6 month mark

  20. Cost

    Measured by time sheets, receipts, and budget to analyze CHW salary/benefits

    Time frame: 6 months (post-intervention)

  21. Cost

    Measured by time sheets, receipts, and budget to analyze CHW equipment

    Time frame: 6 months (post-intervention)

  22. Cost

    Measured by time sheets, receipts, and budget to analyze CHW consumables

    Time frame: 6 months (post-intervention)

  23. YA-URM Autonomy/ Competence, Social Support

    Measured using the Healthcare Self-Determination survey

    Time frame: Baseline

  24. YA-URM Autonomy/ Competence, Social Support

    Measured using the Healthcare Self-Determination survey

    Time frame: 3 month mark

  25. YA-URM Autonomy/ Competence, Social Support

    Measured using the Healthcare Self-Determination survey

    Time frame: 6 month mark

  26. YA-URM Autonomy/ Competence, Social Support

    Measured using the Healthcare Self-Determination survey

    Time frame: 9 month mark

  27. Hemoglobin A1c

    Obtained by POC (in clinic) or laboratory (DCA Vantage)

    Time frame: Baseline

  28. Hemoglobin A1c

    Obtained by POC (in clinic) or laboratory (DCA Vantage)

    Time frame: 3 month mark

  29. Hemoglobin A1c

    Obtained by POC (in clinic) or laboratory (DCA Vantage)

    Time frame: 6 month mark

  30. Hemoglobin A1c

    Obtained by POC (in clinic) or laboratory (DCA Vantage)

    Time frame: 9 month mark

  31. Quality of Life (Diabetes Distress)

    Validated survey: Type 1 Diabetes and Life Scale - Young Adult (T1DAL-YA) Likert Scale: 1-5 (1= no, not at all true, 2=no, not very true, 3=sometimes true, sometimes not true, 4=yes, a little true, 5= yes, very true)

    Time frame: Baseline

  32. Quality of Life (Diabetes Distress)

    Validated surveys: Problem Areas in Diabetes (PAID) The scores for each item are summed, then multiplied by 1.25 to generate a total score out of 100. * Total scores of 40 and above: severe diabetes distress * Individual items scored 3 or 4: moderate to severe distress to be discussed during the appointment following completion of the questionnaire.

    Time frame: Baseline

  33. Quality of Life (Diabetes Distress)

    Validated survey: Diabetes Self-Management Questionnaire (DSMQ)

    Time frame: Baseline

  34. Quality of Life (Diabetes Distress)

    Validated survey: Healthcare Climate Questionnaire (HCCQ) Likert Scale (1-7) 1= strongly disagree ---- 7= strongly agree Higher average scores represent a higher level of perceived autonomy support.

    Time frame: Baseline

  35. Quality of Life (Diabetes Distress)

    Validated survey: Type 1 Diabetes and Life Scale - Young Adult (T1DAL-YA) Likert Scale: 1-5 (1= no, not at all true, 2=no, not very true, 3=sometimes true, sometimes not true, 4=yes, a little true, 5= yes, very true)

    Time frame: 3 month follow-up

  36. Quality of Life (Diabetes Distress)

    Validated surveys: Problem Areas in Diabetes (PAID) The scores for each item are summed, then multiplied by 1.25 to generate a total score out of 100. * Total scores of 40 and above: severe diabetes distress * Individual items scored 3 or 4: moderate to severe distress to be discussed during the appointment following completion of the questionnaire.

    Time frame: 3 month follow-up

  37. Quality of Life (Diabetes Distress)

    Validated survey: Diabetes Self-Management Questionnaire (DSMQ)

    Time frame: 3 month follow-up

  38. Quality of Life (Diabetes Distress)

    Validated survey: Healthcare Climate Questionnaire (HCCQ) Likert Scale (1-7) 1= strongly disagree ---- 7= strongly agree Higher average scores represent a higher level of perceived autonomy support.

    Time frame: 3 month follow-up

  39. Quality of Life (Diabetes Distress

    Validated survey: Type 1 Diabetes and Life Scale - Young Adult (T1DAL-YA) Likert Scale: 1-5 (1= no, not at all true, 2=no, not very true, 3=sometimes true, sometimes not true, 4=yes, a little true, 5= yes, very true)

    Time frame: 6 month follow-up

  40. Quality of Life (Diabetes Distress)

    Validated surveys: Problem Areas in Diabetes (PAID) The scores for each item are summed, then multiplied by 1.25 to generate a total score out of 100. * Total scores of 40 and above: severe diabetes distress * Individual items scored 3 or 4: moderate to severe distress to be discussed during the appointment following completion of the questionnaire.

    Time frame: 6 month follow-up

  41. Quality of Life (Diabetes Distress)

    Validated survey: Diabetes Self-Management Questionnaire (DSMQ)

    Time frame: 6 month follow-up

  42. Quality of Life (Diabetes Distress)

    Validated survey: Healthcare Climate Questionnaire (HCCQ) Likert Scale (1-7) 1= strongly disagree ---- 7= strongly agree Higher average scores represent a higher level of perceived autonomy support.

    Time frame: 6 month follow-up

08

Results

Posted Nov 12, 2026

Participant flow

Participant flow — Overall Study
MilestoneT1D-CATCHUsual Endocrine Care Control Condition
Started5960
Completed5756
Not completed24
Withdrew: Lost to follow-up24

Outcome measures

PrimaryTechnology Initiation

Technology initiation will be assessed by the percentage of participants initiating diabetes technology and will be reported as a binary variable (yes/no). Technology will include any combination of continuous glucose monitor (CGM), insulin pump, or CGM and insulin pump. Technology initiation will be defined as at least 1 week of first use during the 6-month period following intervention. Data will be ascertained from electronic medical record (EMR) prescriptions, participant self-reporting, CHW dashboard, and device platform data. Variables will be summarized by study group using summary statistics with counts/percentages.

Time frame:
Up to 6 months after initiating intervention
Reported as:
Count of participants · Participants
Technology Initiation
ParticipantsT1D-CATCHUsual Endocrine Care Control Condition
Technology Initiation3614
Statistical analysis
  • T1D-CATCH vs Usual Endocrine Care Control Condition · Mixed Models Analysis · p = 0.00007 · Odds ratio (or): 5.1 · 95% CI 2.3 to 11.2Reported estimate is the interaction coefficient at 6 months, a difference-in-differences estimate adjusted for baseline.
SecondaryTechnology Initiation

Technology initiation will be assessed by the percentage of participants initiating diabetes technology and will be reported as a binary variable (yes/no). Technology will include any combination of continuous glucose monitor (CGM), insulin pump, or CGM and insulin pump. Technology initiation will be defined as at least 1 week of first use during the 3-month period following intervention. Data will be ascertained from electronic medical record (EMR) prescriptions, participant self-reporting, CHW dashboard, and device platform data. Variables will be summarized by study group using summary statistics with counts/percentages.

Time frame:
Up to 3 months after initiating intervention
Reported as:
Count of participants · Participants
Technology Initiation
ParticipantsT1D-CATCHUsual Endocrine Care Control Condition
Technology Initiation269
Statistical analysis
  • T1D-CATCH vs Usual Endocrine Care Control Condition · Mixed Models Analysis · p = 0.00056 · Odds ratio (or): 4.0 · 95% CI 1.7 to 9.4Reported estimate is the interaction coefficient at 3 months, a difference-in-differences estimate adjusted for baseline.
SecondaryContinued Technology Use - Percent Use

Continued technology use by study end will be determined from device platform metrics detailing days/percent time used, in addition to self-report. Per standard diabetes technology clinical trial guidelines, CGM use is defined as pump use \>90% time. The percentage of time used (% used) will be summarized by study arm using basic descriptive statistics. A target of at least 90% CGM wear-time is associated with the best outcomes for glycemic control.

Time frame:
9 months following intervention

Results for this outcome have not been posted.

SecondaryContinued Technology Use - Days of Wear

Continued technology use by study end will be determined from device platform metrics detailing days/percent time used, in addition to self-report. Per standard diabetes technology clinical trial guidelines, CGM use is defined as ≥ 5/7 days wear over the 9 month period. Days of wear will be summarized study arm using basic descriptive statistics. A target of at least 5/7 days of CGM wear-time is associated with the best outcomes for glycemic control.

Time frame:
9 months following intervention

Results for this outcome have not been posted.

Other pre-specifiedFeasibility Check

Post-intervention interviews examining intervention content, complexity, comfort, delivery, and credibility

Time frame:
6 months (post-intervention)

Results for this outcome have not been posted.

Other pre-specifiedAdoption

Measured by recruitment logs

Time frame:
9 months (post-intervention)

Results for this outcome have not been posted.

Other pre-specifiedAdoption

Measured by electronic medical records (EMR)

Time frame:
9 months (post-intervention)

Results for this outcome have not been posted.

Other pre-specifiedAdoption

Measured by young adult participant consent rates

Time frame:
9 months (post-intervention)

Results for this outcome have not been posted.

Other pre-specifiedAdoption

Measured by percentage of provider opt-in

Time frame:
9 months (post-intervention)

Results for this outcome have not been posted.

Other pre-specifiedAdoption

Measured by CHW communications

Time frame:
9 months (post-intervention)

Results for this outcome have not been posted.

Other pre-specifiedFidelity

Measured by the community health worker (CHW) dashboard

Time frame:
Baseline

Results for this outcome have not been posted.

Other pre-specifiedFidelity

Measured by electronic medical records (EMR) to analyze session attendance

Time frame:
Baseline

Results for this outcome have not been posted.

Other pre-specifiedFidelity

Measured by content delivery

Time frame:
Baseline

Results for this outcome have not been posted.

Other pre-specifiedFidelity

Measured by community health workers (CHW) dashboard

Time frame:
3 month mark

Results for this outcome have not been posted.

Other pre-specifiedFidelity

Measured by CHW session recordings

Time frame:
3 month mark

Results for this outcome have not been posted.

Other pre-specifiedFidelity

Measured by EMR to analyze session attendance

Time frame:
3 month mark

Results for this outcome have not been posted.

Other pre-specifiedFidelity

Measured by content delivery

Time frame:
3 month mark

Results for this outcome have not been posted.

Other pre-specifiedFidelity

Measured by insurance tasks

Time frame:
3 month mark

Results for this outcome have not been posted.

Other pre-specifiedFidelity

Measured by CHW dashboard

Time frame:
6 month mark

Results for this outcome have not been posted.

Other pre-specifiedFidelity

Measured by CHW session recordings

Time frame:
6 month mark

Results for this outcome have not been posted.

Other pre-specifiedFidelity

Measured by EMR to analyze session attendance

Time frame:
6 month mark

Results for this outcome have not been posted.

Other pre-specifiedFidelity

Measured by content delivery

Time frame:
6 month mark

Results for this outcome have not been posted.

Other pre-specifiedFidelity

Measured by insurance tasks

Time frame:
6 month mark

Results for this outcome have not been posted.

Other pre-specifiedCost

Measured by time sheets, receipts, and budget to analyze CHW salary/benefits

Time frame:
6 months (post-intervention)

Results for this outcome have not been posted.

Other pre-specifiedCost

Measured by time sheets, receipts, and budget to analyze CHW equipment

Time frame:
6 months (post-intervention)

Results for this outcome have not been posted.

Other pre-specifiedCost

Measured by time sheets, receipts, and budget to analyze CHW consumables

Time frame:
6 months (post-intervention)

Results for this outcome have not been posted.

Other pre-specifiedYA-URM Autonomy/ Competence, Social Support

Measured using the Healthcare Self-Determination survey

Time frame:
Baseline

Results for this outcome have not been posted.

Other pre-specifiedYA-URM Autonomy/ Competence, Social Support

Measured using the Healthcare Self-Determination survey

Time frame:
3 month mark

Results for this outcome have not been posted.

Other pre-specifiedYA-URM Autonomy/ Competence, Social Support

Measured using the Healthcare Self-Determination survey

Time frame:
6 month mark

Results for this outcome have not been posted.

Other pre-specifiedYA-URM Autonomy/ Competence, Social Support

Measured using the Healthcare Self-Determination survey

Time frame:
9 month mark

Results for this outcome have not been posted.

Other pre-specifiedHemoglobin A1c

Obtained by POC (in clinic) or laboratory (DCA Vantage)

Time frame:
Baseline

Results for this outcome have not been posted.

Other pre-specifiedHemoglobin A1c

Obtained by POC (in clinic) or laboratory (DCA Vantage)

Time frame:
3 month mark

Results for this outcome have not been posted.

Other pre-specifiedHemoglobin A1c

Obtained by POC (in clinic) or laboratory (DCA Vantage)

Time frame:
6 month mark

Results for this outcome have not been posted.

Other pre-specifiedHemoglobin A1c

Obtained by POC (in clinic) or laboratory (DCA Vantage)

Time frame:
9 month mark

Results for this outcome have not been posted.

Other pre-specifiedQuality of Life (Diabetes Distress)

Validated survey: Type 1 Diabetes and Life Scale - Young Adult (T1DAL-YA) Likert Scale: 1-5 (1= no, not at all true, 2=no, not very true, 3=sometimes true, sometimes not true, 4=yes, a little true, 5= yes, very true)

Time frame:
Baseline

Results for this outcome have not been posted.

Other pre-specifiedQuality of Life (Diabetes Distress)

Validated surveys: Problem Areas in Diabetes (PAID) The scores for each item are summed, then multiplied by 1.25 to generate a total score out of 100. * Total scores of 40 and above: severe diabetes distress * Individual items scored 3 or 4: moderate to severe distress to be discussed during the appointment following completion of the questionnaire.

Time frame:
Baseline

Results for this outcome have not been posted.

Other pre-specifiedQuality of Life (Diabetes Distress)

Validated survey: Diabetes Self-Management Questionnaire (DSMQ)

Time frame:
Baseline

Results for this outcome have not been posted.

Other pre-specifiedQuality of Life (Diabetes Distress)

Validated survey: Healthcare Climate Questionnaire (HCCQ) Likert Scale (1-7) 1= strongly disagree ---- 7= strongly agree Higher average scores represent a higher level of perceived autonomy support.

Time frame:
Baseline

Results for this outcome have not been posted.

Other pre-specifiedQuality of Life (Diabetes Distress)

Validated survey: Type 1 Diabetes and Life Scale - Young Adult (T1DAL-YA) Likert Scale: 1-5 (1= no, not at all true, 2=no, not very true, 3=sometimes true, sometimes not true, 4=yes, a little true, 5= yes, very true)

Time frame:
3 month follow-up

Results for this outcome have not been posted.

Other pre-specifiedQuality of Life (Diabetes Distress)

Validated surveys: Problem Areas in Diabetes (PAID) The scores for each item are summed, then multiplied by 1.25 to generate a total score out of 100. * Total scores of 40 and above: severe diabetes distress * Individual items scored 3 or 4: moderate to severe distress to be discussed during the appointment following completion of the questionnaire.

Time frame:
3 month follow-up

Results for this outcome have not been posted.

Other pre-specifiedQuality of Life (Diabetes Distress)

Validated survey: Diabetes Self-Management Questionnaire (DSMQ)

Time frame:
3 month follow-up

Results for this outcome have not been posted.

Other pre-specifiedQuality of Life (Diabetes Distress)

Validated survey: Healthcare Climate Questionnaire (HCCQ) Likert Scale (1-7) 1= strongly disagree ---- 7= strongly agree Higher average scores represent a higher level of perceived autonomy support.

Time frame:
3 month follow-up

Results for this outcome have not been posted.

Other pre-specifiedQuality of Life (Diabetes Distress

Validated survey: Type 1 Diabetes and Life Scale - Young Adult (T1DAL-YA) Likert Scale: 1-5 (1= no, not at all true, 2=no, not very true, 3=sometimes true, sometimes not true, 4=yes, a little true, 5= yes, very true)

Time frame:
6 month follow-up

Results for this outcome have not been posted.

Other pre-specifiedQuality of Life (Diabetes Distress)

Validated surveys: Problem Areas in Diabetes (PAID) The scores for each item are summed, then multiplied by 1.25 to generate a total score out of 100. * Total scores of 40 and above: severe diabetes distress * Individual items scored 3 or 4: moderate to severe distress to be discussed during the appointment following completion of the questionnaire.

Time frame:
6 month follow-up

Results for this outcome have not been posted.

Other pre-specifiedQuality of Life (Diabetes Distress)

Validated survey: Diabetes Self-Management Questionnaire (DSMQ)

Time frame:
6 month follow-up

Results for this outcome have not been posted.

Other pre-specifiedQuality of Life (Diabetes Distress)

Validated survey: Healthcare Climate Questionnaire (HCCQ) Likert Scale (1-7) 1= strongly disagree ---- 7= strongly agree Higher average scores represent a higher level of perceived autonomy support.

Time frame:
6 month follow-up

Results for this outcome have not been posted.

Adverse events

Collected over Up to 6 months following initiation of intervention. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
T1D-CATCH0/59 (0%)14/59 (23.7%)5/59 (8.5%)
Usual Endocrine Care Control Condition0/60 (0%)24/60 (40%)8/60 (13.3%)
Most frequent serious events
Most frequent serious events
EventT1D-CATCHUsual Endocrine Care Control Condition
Diabetic KetoacidosisEndocrine disorders7/5916/60
Car Accident or AltercationSocial circumstances4/591/60
GastroenteritisGastrointestinal disorders3/594/60
Chest painCardiac disorders2/593/60
Most frequent other events
Most frequent other events
EventT1D-CATCHUsual Endocrine Care Control Condition
Stomach painGastrointestinal disorders3/595/60
Eye pain/ConjunctivitisEye disorders2/593/60

Baseline characteristics

Age, Continuous
Age, Continuous(years)T1D-CATCHUsual Endocrine Care Control ConditionTotal
Mean25.0 ± 4.724.8 ± 4.324.9 ± 4.5
Sex: Female, Male
Sex: Female, Male(Participants)T1D-CATCHUsual Endocrine Care Control ConditionTotal
Female302757
Male293362
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)T1D-CATCHUsual Endocrine Care Control ConditionTotal
Non-Hispanic Black172037
Hispanic424082
Region of Enrollment
Region of Enrollment(participants)T1D-CATCHUsual Endocrine Care Control ConditionTotal
United States5960119
Primary Insurance
Primary Insurance(Participants)T1D-CATCHUsual Endocrine Care Control ConditionTotal
Private121123
Public474996
Education
Education(Participants)T1D-CATCHUsual Endocrine Care Control ConditionTotal
Some High School7411
High School/General Educational Development (GED)212445
Some College221638
Associate Degree3710
Bachelor's Degree448
Data Unavailable/Missing257
Number of Participants with Any Health-Related Social Need
Number of Participants with Any Health-Related Social Need(Participants)T1D-CATCHUsual Endocrine Care Control ConditionTotal
Count of participants283361
Diabetes Distress based on Problem Areas in Diabetes-11 (PAID-11) survey
Diabetes Distress based on Problem Areas in Diabetes-11 (PAID-11) survey(score on a scale)T1D-CATCHUsual Endocrine Care Control ConditionTotal
Mean19 ± 1117 ± 1118 ± 11

2 further baseline measures are reported on the registry.

09

Study locations

1 site
  • Albert Einstein College of Medicine
    The Bronx, New York 10461, United States
10

References and documents

Publications

  • Agarwal S, Schechter C, Gonzalez J, Long JA. Racial-Ethnic Disparities in Diabetes Technology use Among Young Adults with Type 1 Diabetes. Diabetes Technol Ther. 2021 Apr;23(4):306-313. doi: 10.1089/dia.2020.0338. Epub 2020 Dec 1. PubMed 33155826 ↗
  • Willi SM, Miller KM, DiMeglio LA, Klingensmith GJ, Simmons JH, Tamborlane WV, Nadeau KJ, Kittelsrud JM, Huckfeldt P, Beck RW, Lipman TH; T1D Exchange Clinic Network. Racial-ethnic disparities in management and outcomes among children with type 1 diabetes. Pediatrics. 2015 Mar;135(3):424-34. doi: 10.1542/peds.2014-1774. PubMed 25687140 ↗
  • Livingstone SJ, Levin D, Looker HC, Lindsay RS, Wild SH, Joss N, Leese G, Leslie P, McCrimmon RJ, Metcalfe W, McKnight JA, Morris AD, Pearson DW, Petrie JR, Philip S, Sattar NA, Traynor JP, Colhoun HM; Scottish Diabetes Research Network epidemiology group; Scottish Renal Registry. Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008-2010. JAMA. 2015 Jan 6;313(1):37-44. doi: 10.1001/jama.2014.16425. PubMed 25562264 ↗
  • Foster NC, Beck RW, Miller KM, Clements MA, Rickels MR, DiMeglio LA, Maahs DM, Tamborlane WV, Bergenstal R, Smith E, Olson BA, Garg SK. State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016-2018. Diabetes Technol Ther. 2019 Feb;21(2):66-72. doi: 10.1089/dia.2018.0384. Epub 2019 Jan 18. PubMed 30657336 ↗
  • McKergow E, Parkin L, Barson DJ, Sharples KJ, Wheeler BJ. Demographic and regional disparities in insulin pump utilization in a setting of universal funding: a New Zealand nationwide study. Acta Diabetol. 2017 Jan;54(1):63-71. doi: 10.1007/s00592-016-0912-7. Epub 2016 Sep 20. PubMed 27650535 ↗
  • Agarwal S, Crespo-Ramos G, Long JA, Miller VA. "I Didn't Really Have a Choice": Qualitative Analysis of Racial-Ethnic Disparities in Diabetes Technology Use Among Young Adults with Type 1 Diabetes. Diabetes Technol Ther. 2021 Sep;23(9):616-622. doi: 10.1089/dia.2021.0075. PubMed 33761284 ↗
  • Lai CW, Lipman TH, Willi SM, Hawkes CP. Racial and Ethnic Disparities in Rates of Continuous IRB NUMBER: 2021-13714 IRB APPROVAL DATE: 03/23/2022 Glucose Monitor Initiation and Continued Use in Children With Type 1 Diabetes. 2020;(Online ahead of print). doi:10.2337/dc20-1663
  • Addala A, Auzanneau M, Miller K, Maier W, Foster N, Kapellen T, Walker A, Rosenbauer J, Maahs DM, Holl RW. A Decade of Disparities in Diabetes Technology Use and HbA1c in Pediatric Type 1 Diabetes: A Transatlantic Comparison. Diabetes Care. 2021 Jan;44(1):133-140. doi: 10.2337/dc20-0257. Epub 2020 Sep 16. PubMed 32938745 ↗
  • Addala A, Hanes S, Naranjo D, Maahs DM, Hood KK. Provider Implicit Bias Impacts Pediatric Type 1 Diabetes Technology Recommendations in the United States: Findings from The Gatekeeper Study. J Diabetes Sci Technol. 2021 Sep;15(5):1027-1033. doi: 10.1177/19322968211006476. Epub 2021 Apr 15. PubMed 33858206 ↗
  • Walker AF, Hood KK, Gurka MJ, Filipp SL, Anez-Zabala C, Cuttriss N, Haller MJ, Roque X, Naranjo D, Aulisio G, Addala A, Konopack J, Westen S, Yabut K, Mercado E, Look S, Fitzgerald B, Maizel J, Maahs DM. Barriers to Technology Use and Endocrinology Care for Underserved Communities With Type 1 Diabetes. Diabetes Care. 2021 Jul;44(7):1480-1490. doi: 10.2337/dc20-2753. Epub 2021 May 17. PubMed 34001535 ↗
  • Findley SE, Matos S, Hicks AL, Campbell A, Moore A, Diaz D. Building a consensus on community health workers' scope of practice: lessons from New York. Am J Public Health. 2012 Oct;102(10):1981-7. doi: 10.2105/AJPH.2011.300566. Epub 2012 Aug 16. PubMed 22897548 ↗
  • Saydah S, Imperatore G, Cheng Y, Geiss LS, Albright A. Disparities in Diabetes Deaths Among Children and Adolescents - United States, 2000-2014. MMWR Morb Mortal Wkly Rep. 2017 May 19;66(19):502-505. doi: 10.15585/mmwr.mm6619a4. PubMed 28520705 ↗
  • Walker RJ, Gebregziabher M, Martin-Harris B, Egede LE. Independent effects of socioeconomic and psychological social determinants of health on self-care and outcomes in Type 2 diabetes. Gen Hosp Psychiatry. 2014 Nov-Dec;36(6):662-8. doi: 10.1016/j.genhosppsych.2014.06.011. Epub 2014 Jul 9. PubMed 25103544 ↗
  • Walker RJ, Gebregziabher M, Martin-Harris B, Egede LE. Quantifying direct effects of social determinants of health on glycemic control in adults with type 2 diabetes. Diabetes Technol Ther. 2015 Feb;17(2):80-7. doi: 10.1089/dia.2014.0166. Epub 2014 Oct 31. PubMed 25361382 ↗
  • Berkowitz SA, Meigs JB, DeWalt D, Seligman HK, Barnard LS, Bright OJ, Schow M, Atlas SJ, Wexler DJ. Material need insecurities, control of diabetes mellitus, and use of health care resources: results of the Measuring Economic Insecurity in Diabetes study. JAMA Intern Med. 2015 Feb;175(2):257-65. doi: 10.1001/jamainternmed.2014.6888. PubMed 25545780 ↗
  • Berkowitz SA, Kalkhoran S, Edwards ST, Essien UR, Baggett TP. Unstable Housing and Diabetes-Related Emergency Department Visits and Hospitalization: A Nationally Representative Study of Safety-Net Clinic Patients. Diabetes Care. 2018 May;41(5):933-939. doi: 10.2337/dc17-1812. Epub 2018 Jan 4. PubMed 29301822 ↗
  • Hall WJ, Chapman MV, Lee KM, Merino YM, Thomas TW, Payne BK, Eng E, Day SH, Coyne-Beasley T. Implicit Racial/Ethnic Bias Among Health Care Professionals and Its Influence on Health Care Outcomes: A Systematic Review. Am J Public Health. 2015 Dec;105(12):e60-76. doi: 10.2105/AJPH.2015.302903. Epub 2015 Oct 15. PubMed 26469668 ↗
  • Hagiwara N, Elston Lafata J, Mezuk B, Vrana SR, Fetters MD. Detecting implicit racial bias in provider communication behaviors to reduce disparities in healthcare: Challenges, solutions, and future directions for provider communication training. Patient Educ Couns. 2019 Sep;102(9):1738-1743. doi: 10.1016/j.pec.2019.04.023. Epub 2019 Apr 19. PubMed 31036330 ↗
  • Franklin CM, Bernhardt JM, Lopez RP, Long-Middleton ER, Davis S. Interprofessional Teamwork and Collaboration Between Community Health Workers and Healthcare Teams: An Integrative Review. Health Serv Res Manag Epidemiol. 2015 Mar 16;2:2333392815573312. doi: 10.1177/2333392815573312. eCollection 2015 Jan-Dec. PubMed 28462254 ↗
  • Schaaf M, Warthin C, Freedman L, Topp SM. The community health worker as service extender, cultural broker and social change agent: a critical interpretive synthesis of roles, intent and accountability. BMJ Glob Health. 2020 Jun;5(6):e002296. doi: 10.1136/bmjgh-2020-002296. PubMed 32546585 ↗
  • C3 Project. The Community Health Worker Core Consensus Project (C3): Roles and Competencies. C3 Project Findings. Published 2018. Accessed April 29, 2021. https://www.c3project.org/roles-competencies
  • Palmas W, March D, Darakjy S, Findley SE, Teresi J, Carrasquillo O, Luchsinger JA. Community Health Worker Interventions to Improve Glycemic Control in People with Diabetes: A Systematic Review and Meta-Analysis. J Gen Intern Med. 2015 Jul;30(7):1004-12. doi: 10.1007/s11606-015-3247-0. Epub 2015 Mar 4. PubMed 25735938 ↗
  • Ballard M, Westgate C, Alban R, Choudhury N, Adamjee R, Schwarz R, Bishop J, McLaughlin M, Flood D, Finnegan K, Rogers A, Olsen H, Johnson A, Palazuelos D, Schechter J. Compensation models for community health workers: Comparison of legal frameworks across five countries. J Glob Health. 2021 Feb 15;11:04010. doi: 10.7189/jogh.11.04010. PubMed 33692894 ↗
  • Spencer MS, Kieffer EC, Sinco B, Piatt G, Palmisano G, Hawkins J, Lebron A, Espitia N, Tang T, Funnell M, Heisler M. Outcomes at 18 Months From a Community Health Worker and Peer Leader Diabetes Self-Management Program for Latino Adults. Diabetes Care. 2018 Jul;41(7):1414-1422. doi: 10.2337/dc17-0978. Epub 2018 Apr 27. PubMed 29703724 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

11

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2022 to primary completion in Sep 2025, 34 months.

Results were first posted in Nov 2026, 1 year 2 months after primary completion.

Of 852 non-industry interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's 34 months is above that.

Counting every sponsor, half of 957 studies reached it within 18 months; a quarter within 9 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2021
First posted
Jan 27, 2022
StartActual
Nov 7, 2022
Primary completionActual
Sep 8, 2025
CompletionActual
Dec 8, 2025
Results first posted
Nov 12, 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 12, 2026
Primary outcomes
1 time frame changed, 1 description edited
What changed in the outcomes
  • Time frameTechnology Initiation6 months following intervention → Up to 6 months after initiating intervention
  • DescriptionTechnology Initiation: how it is measured was reworded
Nov 12, 2026
Secondary outcomes
2 edited, 1 time frame changed, 2 description edited
What changed in the outcomes
  • EditedContinued Technology Use - Days of wearWearTime frame: 9 months following intervention
  • Time frameTechnology Initiation3 months following intervention → Up to 3 months after initiating intervention
  • DescriptionTechnology Initiation: how it is measured was reworded
  • Editedother outcomeQuality of lifeLife (Diabetes Distress)Time frame: 6 month follow-up
  • Descriptionother outcomeQuality of Life (Diabetes Distress)#10: how it is measured was reworded
Nov 12, 2026
Title
T1DTechCHW: Enhancing the Community Health Worker Model to Promote Diabetes Technology Use in Young Adults From Underrepresented Minority Groups→T1D-CATCH Protocol: Collaboration Around Technology Using Community Health Workers for Young Adults With Type 1 Diabetes
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Results posted
    Primary outcomes 1 time frame changed, 1 description edited
    What changed in the outcomes
    • Time frameTechnology Initiation6 months following intervention → Up to 6 months after initiating intervention
    • DescriptionTechnology Initiation: how it is measured was reworded
    Secondary outcomes 2 edited, 1 time frame changed, 2 description edited
    What changed in the outcomes
    • EditedContinued Technology Use - Days of wearWearTime frame: 9 months following intervention
    • Time frameTechnology Initiation3 months following intervention → Up to 3 months after initiating intervention
    • DescriptionTechnology Initiation: how it is measured was reworded
    • Editedother outcomeQuality of lifeLife (Diabetes Distress)Time frame: 6 month follow-up
    • Descriptionother outcomeQuality of Life (Diabetes Distress)#10: how it is measured was reworded
    Title T1DTechCHW: Enhancing the Community Health Worker Model to Promote Diabetes Technology Use in Young Adults From Underrepresented Minority Groups→T1D-CATCH Protocol: Collaboration Around Technology Using Community Health Workers for Young Adults With Type 1 Diabetes
    + 2 other changes: verification date and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

12

Registry details

Key details

Study ID
NCT05211869
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), The Leona M. and Harry B. Helmsley Charitable Trust
Responsible party
Sponsor
First posted
Jan 27, 2022
Start date
Nov 7, 2022
Primary completion
Sep 8, 2025
Completion
Dec 8, 2025
Results posted
Nov 12, 2026
Last update
Nov 12, 2026

Study contacts

Shivani Agarwal, MD, MPH
principal investigator · Albert Einstein College of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion